GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (STU:29TA) » Definitions » Cyclically Adjusted Price-to-FCF

TherapeuticsMD (STU:29TA) Cyclically Adjusted Price-to-FCF : (As of Jun. 07, 2024)


View and export this data going back to 2014. Start your Free Trial

What is TherapeuticsMD Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


TherapeuticsMD Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for TherapeuticsMD's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TherapeuticsMD Cyclically Adjusted Price-to-FCF Chart

TherapeuticsMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

TherapeuticsMD Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of TherapeuticsMD's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TherapeuticsMD's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where TherapeuticsMD's Cyclically Adjusted Price-to-FCF falls into.



TherapeuticsMD Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

TherapeuticsMD's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, TherapeuticsMD's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.018/131.7762*131.7762
=-0.018

Current CPI (Mar. 2024) = 131.7762.

TherapeuticsMD Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -2.579 100.560 -3.380
201409 -2.916 100.428 -3.826
201412 -4.073 99.070 -5.418
201503 -5.423 99.621 -7.173
201506 -6.421 100.684 -8.404
201509 -4.645 100.392 -6.097
201512 -4.401 99.792 -5.812
201603 -4.508 100.470 -5.913
201606 -3.584 101.688 -4.644
201609 -4.305 101.861 -5.569
201612 -3.860 101.863 -4.994
201703 -4.883 102.862 -6.256
201706 -4.028 103.349 -5.136
201709 -3.380 104.136 -4.277
201712 -4.212 104.011 -5.336
201803 -3.711 105.290 -4.645
201806 -4.990 106.317 -6.185
201809 -10.220 106.507 -12.645
201812 -5.275 105.998 -6.558
201903 -7.129 107.251 -8.759
201906 -9.485 108.070 -11.566
201909 -5.180 108.329 -6.301
201912 -12.294 108.420 -14.942
202003 -6.593 108.902 -7.978
202006 -9.202 108.767 -11.149
202009 -5.344 109.815 -6.413
202012 -4.423 109.897 -5.304
202103 -4.695 111.754 -5.536
202106 -2.804 114.631 -3.223
202109 -3.866 115.734 -4.402
202112 -4.249 117.630 -4.760
202203 -1.906 121.301 -2.071
202206 -2.248 125.017 -2.370
202209 1.933 125.227 2.034
202212 2.628 125.222 2.766
202303 -0.833 127.348 -0.862
202306 -0.306 128.729 -0.313
202309 -0.528 129.860 -0.536
202312 -0.412 129.419 -0.420
202403 -0.018 131.776 -0.018

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


TherapeuticsMD  (STU:29TA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


TherapeuticsMD Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of TherapeuticsMD's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


TherapeuticsMD (STU:29TA) Business Description

Traded in Other Exchanges
Address
951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431
TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.

TherapeuticsMD (STU:29TA) Headlines

No Headlines